Financial Performance - The company's revenue for Q1 2025 was ¥315,110,184.08, a decrease of 26.58% compared to ¥429,172,675.52 in the same period last year[5] - Net profit attributable to shareholders was ¥15,201,816.26, down 47.29% from ¥28,838,483.33 year-on-year[5] - The basic earnings per share decreased by 46.57% to ¥0.0249 from ¥0.0466 in the same period last year[5] - Total operating revenue decreased to ¥315,110,184.08 from ¥429,172,675.52, representing a decline of approximately 26.6% year-over-year[19] - Net profit for the period was ¥11,227,654.31, down from ¥24,958,440.91, indicating a decline of approximately 55.1% year-over-year[19] - Total comprehensive income attributable to the parent company's owners was CNY 16,503,593.60, a decrease from CNY 28,166,335.28 in the previous period, representing a decline of approximately 41.6%[21] - Basic and diluted earnings per share were both CNY 0.0249, down from CNY 0.0466, indicating a decrease of about 46.5%[21] Cash Flow - The net cash flow from operating activities was -¥17,285,740.15, a decline of 117.05% compared to ¥101,357,363.89 in the previous year[5] - The company reported a decrease in sales expenses to ¥41,035,894.57 from ¥68,543,940.69, reflecting a cost-cutting strategy[19] - Net cash flow from operating activities was negative CNY 17,285,740.15, compared to positive CNY 101,357,363.89 in the previous period, reflecting a significant decline[22] - Cash inflow from investment activities totaled CNY 2,872,578.72, an increase from CNY 1,967,181.53 year-over-year[22] - Cash outflow from investment activities was CNY 25,332,665.92, down from CNY 166,170,288.90, indicating a reduction of approximately 84.8%[22] - Net cash flow from financing activities was negative CNY 59,487,257.84, compared to positive CNY 27,980,960.68 in the previous period, showing a reversal in cash flow[22] - The ending balance of cash and cash equivalents was CNY 44,302,664.88, down from CNY 183,656,176.46, a decrease of about 76.1%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,271,069,770.54, a decrease of 1.30% from ¥4,327,397,080.53 at the end of the previous year[5] - Total liabilities decreased to ¥1,501,478,651.87 from ¥1,570,954,359.63, showing a reduction of about 4.4%[18] - Non-current liabilities totaled ¥332,227,294.64, an increase from ¥254,681,402.98, representing a growth of approximately 30.4%[18] - As of the end of the reporting period, the company's total current assets amounted to approximately CNY 1.75 billion, a decrease from CNY 1.80 billion at the beginning of the period[16] Government Support and Subsidies - The company received government subsidies amounting to ¥27,691,508.52, which positively impacted the financial results[6] Research and Development - Research and development expenses were ¥12,774,780.81, slightly down from ¥13,058,050.61, indicating a continued commitment to innovation despite revenue challenges[19] - Wanbangde Pharmaceutical received approval from the National Medical Products Administration for the supplement application of Cefaclor granules, which is considered to have passed the consistency evaluation of generic drug quality and efficacy, enhancing market competitiveness[11] - The company obtained FDA approval for clinical trials of WP107 (Huperzine A oral solution) for treating generalized myasthenia gravis and WP103 (Huperzine A injection) for treating neonatal hypoxic-ischemic encephalopathy, marking a significant step in new drug development[12] - The FDA granted orphan drug designation for Mecobalamin for the treatment of Amyotrophic Lateral Sclerosis (ALS), providing various incentives for drug development and commercialization in the U.S. market[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,646, with the largest shareholder holding 31.37% of the shares[9] - The company completed the repurchase of 5 million shares in March 2022, which were subsequently canceled due to the inability to complete the employee stock ownership plan within the effective period[15]

4月29日，万邦德今日收盘5.81元，上涨1.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到64.63倍，总市值35.83亿元。 从行业市盈率排名来看，公司所处的化学制药行业市盈率平均45.68倍，行业中值26.55倍，万邦德排名 第119位。 万邦德医药控股集团股份有限公司主营业务为现代中药、化学原料药及化学制剂的研发、生产和销售以 及提供高端医疗器械研制、医疗设备服务和提供医院工程服务。主要产品是心脑血管系统主导产品、神 经系统主导产品、呼吸系统主导产品、消化系统主导产品、精神系统主导产品、骨科植入器械、医疗设 备及医院工程服务、一次性无菌医用高分子耗材、防护用品。 最新一期业绩显示，2024年年报，公司实现营业收入14.43亿元，同比-6.39%；净利润5544.10万元，同 比12.66%，销售毛利率41.83%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)119万邦德64.6364.631.3435.83亿行业平均 45.6845.545.50119.08亿行业中值26.5527.442.1948.23亿1上海谊众-1095.821259.436.1787.85亿2 ...

Financial Performance - The company's investment income increased by 593.87% compared to the same period last year, primarily due to the termination of recognition of financial assets measured at amortized cost as investment income [1] - Fair value changes resulted in a loss of 4.7671 million yuan, an increase compared to the same period last year, mainly due to changes in the fair value of other non-current financial assets [1] - Asset impairment losses increased by 149.00% year-on-year, mainly due to the impairment provision for intangible assets (trademarks and patents) of the subsidiary Kangci Medical [1] - Credit impairment losses decreased by 103.81% year-on-year, mainly due to changes in the provision for bad debts of receivables [1] - Asset disposal income increased by 15.6225 million yuan, primarily from the disposal of land and properties of the subsidiary Kangci Medical located in Jiangshan [1] - Non-operating income decreased by 6.7666 million yuan compared to the same period last year, mainly due to a decrease in other non-operating income [1] Cash Flow Analysis - The net cash flow from operating activities increased by 193 million yuan year-on-year, mainly due to an increase in the recovery of accounts receivable and an increase in the use of payable notes for purchasing goods [4] - Cash inflow from investment activities increased by 317.55% year-on-year, primarily due to the disposal of land and properties of the subsidiary Kangci Medical [4] - The net cash flow from financing activities decreased by 557.32% year-on-year, mainly due to an increase in debt repayment during the reporting period [4] Profit Distribution Plan - The company plans not to distribute profits for the 2024 fiscal year, which includes no cash dividends, no bonus shares, and no capital reserve conversion to share capital, with the remaining undistributed profits carried forward to the next year [8][9] - The decision is based on the company's current operational development plans and the need to ensure funding for ongoing projects and R&D [8][9] Asset Impairment Provision - The company plans to recognize an asset impairment provision of 26.2414 million yuan for the fiscal year 2024, following a comprehensive review of various asset categories [10][19] - The provision includes specific amounts for receivables, inventory, and intangible assets, reflecting a cautious approach to financial reporting [12][14][16] Credit and Financial Support - The company intends to apply for a comprehensive credit limit of up to 2.1 billion yuan for 2025 to meet the funding needs of its various business developments [23] - The company also plans to provide financial assistance to its subsidiary, Kangci Medical, with a borrowing limit of up to 50 million yuan at an interest rate of 4% [46][48]

Core Viewpoint - The company reported a 12.66% year-on-year increase in net profit attributable to shareholders, reaching 55.44 million yuan, and achieved a positive operating cash flow of 120 million yuan in 2024, highlighting significant improvements in its financial performance [1] Financial Performance - The company's net profit attributable to shareholders increased by 12.66% year-on-year, amounting to 55.44 million yuan [1] - Operating cash flow turned positive, achieving 120 million yuan in 2024 [1] - The medical device segment significantly reduced losses by 42.49%, while the South African business turned profitable with a year-on-year net profit growth of 211.68% [1][2] Business Segments - The South African business segment achieved profitability after years of effort, marking a key highlight in the company's operational performance [2] - The company has established a strong presence in the medical device sector, with multiple orthopedic implant products certified by the FDA and CE, and a robust pipeline of new products under development [2] - The company has been focusing on the South African market for medical device distribution and maintenance services, building a stable customer base and market reputation [2][3] Innovation and R&D - The company has made significant breakthroughs in new drug development, particularly in the field of neurological drugs, with a focus on the development of the huperzine A series and methionine preparations [1][4] - As of the end of the reporting period, the company had seven new drug pipelines under research, with five of them being dual-filed in China and the U.S., indicating high-quality pipeline development [4] - The company has received FDA clinical trial approvals for WP107 and WP103, both of which are based on huperzine A, a potent cholinesterase inhibitor [4][6] Future Outlook - The company plans to enhance its international strategy by increasing the export of domestic medical devices, aiming to create a new profit contribution point [3] - The company is committed to advancing its R&D capabilities by leveraging artificial intelligence in drug development and production quality control [7] - The company aims to become a leading enterprise in the pharmaceutical and health industry through technological innovation and collaboration with academic institutions [7]

证券代码：002082 证券简称：万邦德 公告编号：2025-029 万邦德医药控股集团股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开第九届董事会第十四次会议，审议通过了《关于召开 2024 年年度股东大 会的议案》，现将有关事项公告如下： 一、召开会议的基本情况 1．股东大会届次：2024 年年度股东大会。 2．会议召集人：公司第九届董事会。 3．会议召开的合法、合规性说明：本次股东大会的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 4．会议召开时间和日期： (1) 现场会议召开的时间：2025 年 5 月 20 日（星期二）下午 14:00。 (2) 网络投票时间： 1) 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年5 月 20 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00； 2) 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 ...

北京德皓国际会计师事务所(特殊普通合伙)（以下简称"北京德皓国际"） 对万邦德医药控股集团股份有限公司（以下简称"公司""万邦德"）2024 年 度内部控制情况进行了审计，出具了带强调事项段无保留意见的内部控制审计报 告。根据《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》等相关 规定，公司董事会就上述意见涉及事项出具了《董事会关于带强调事项段无保留 意见的内部控制审计报告的专项说明》，监事会对上述事项发表意见如下： 万邦德医药控股集团股份有限公司监事会 关于对《董事会关于带强调事项段无保留意见内部控制审计报告 专项说明》的意见 监 事 会 2025 年 4 月 29 日 监事会认为董事会出具的《董事会关于带强调事项段无保留意见的内部控制 审计报告的专项说明》客观反映了公司内部控制的实际情况。后续，监事会将持 续督导董事会与管理层强化内部控制管理，推进内控体系的健全完善，确保内控 制度严格执行与有效落实，切实提升公司内控管理水平，保障全体股东合法权益。 万邦德医药控股集团股份有限公司 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-019 万邦德医药控股集团股份有限公司 第九届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 万邦德医药控股集团股份有限公司（以下简称"公司"）第九届监事会第九 次会议通知于 2025 年 4 月 14 日以电话、邮件、微信等方式发出，并于 2025 年 4 月 22 日发出变更会议时间的通知，会议于 2025 年 4 月 27 日在公司行政楼会议室 以现场方式召开。本次会议由监事会主席王虎根先生主持，应到监事 3 人，实到 监事 3 人，董事会秘书列席了本次会议。会议的召集、召开及表决程序符合有关 法律法规和《公司章程》等有关规定。 二、监事会会议审议情况 会议以记名投票表决的方式审议通过了以下议案： 1.审议通过了《2024 年度监事会工作报告》 表决结果：3 票同意，0 票反对，0 票弃权。 本议案尚需提交公司 2024 年年度股东大会审议。 3.审议通过了《关于 2024 年度利润分配预案的议案》 表决结果：3 票同意，0 票反对，0 票弃权 ...

1、公司结合所处行业特性、经营模式、资产结构及自身特点等，按照《企 业内部控制基本规范》及配套指引等法律、行政法规和部门规章的要求，已建立 了较为完整且符合现阶段发展需要的内部控制制度。 2、公司的内部控制活动依据各项内部控制制度实施，在生产经营的各个环 节实施了有效的内部控制和风险防范，确保了生产经营活动的顺利进行，保护了 公司资产的安全和完整。 报告期内，公司内部控制制度执行情况良好，不存在重大和重要的内部控制 缺陷。监事会认为公司编制的《2024 年度内部控制评价报告》全面、客观、真 实地反映了公司内部控制体系建设和运作的实际情况。 万邦德医药控股集团股份有限公司监事会 对公司内部控制评价报告的审核意见 根据《中华人民共和国公司法》《企业内部控制基本规范》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规和规范性 文件的相关规定，万邦德医药控股集团股份有限公司（以下简称"公司"）监事 会对公司《2024 年度内部控制评价报告》发表审核意见如下： 万邦德医药控股集团股份有限公司 监 事 会 二〇二五年四月二十九日 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-018 万邦德医药控股集团股份有限公司 第九届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 万邦德医药控股集团股份有限公司（以下简称"公司"）第九届董事会第十 四次会议通知于 2025 年 4 月 14 日以邮件、电话、微信等方式发出，并于 2025 年 4 月 22 日发出变更会议时间的通知，会议于 2025 年 4 月 27 日在公司行政楼会 议室以现场结合通讯方式召开。本次会议由董事长赵守明先生主持，应出席会议 董事 9 人，实际出席董事 9 人，屠鹏飞先生以通讯方式出席会议并参与表决。公 司监事及高级管理人员列席会议。会议的召集、召开及表决程序符合有关法律法 规和《公司章程》的规定。 二、董事会会议审议情况 会议以记名投票表决的方式审议通过了以下议案： 1.审议通过《2024 年度总经理工作报告》 表决结果：9 票同意，0 票反对，0 票弃权。 2.审议通过《2024 年度董事会工作报告》 表决结果：9 票同意，0 票反对，0 票弃权。 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-021 万邦德医药控股集团股份有限公司 关于 2024 年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司(以下简称"公司")于 2025 年 4 月 27 日 召开第九届董事会第十四次会议、第九届监事会第九次会议，审议通过了《关于 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年年度股东大会审 议通过。现将有关事项公告如下： 一、2024 年度利润分配方案的基本情况 经 北 京 德 皓 国 际 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） 出 具 的 德 皓 审 字 [2025]00001489 审计报告确认，公司 2024 年度实现净利润 45,248,240.59 元， 归 属 于 母 公 司 所 有 者 的净利润 55,440,971.44 元 ， 公 司 未分配利润 1,655,917,047.36 元；2024 年度母公司实现净利润 13,597,713.20 元，按《公司 章程》规定，提取 10%盈余 ...